AEON Biopharma, Inc. (AEON) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AEON Biopharma, Inc. (AEON) has a cash flow conversion efficiency ratio of 0.131x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.60 Million) by net assets ($-19.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
AEON Biopharma, Inc. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how AEON Biopharma, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read AEON liabilities breakdown for a breakdown of total debt and financial obligations.
AEON Biopharma, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AEON Biopharma, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sarama Resources Ltd
AU:SRR
|
1.779x |
|
Finsbury Growth & Income Trust
LSE:FGT
|
0.013x |
|
Volcano Bhd
KLSE:0232
|
0.027x |
|
Brimstone Investment Corporation Ltd
JSE:BRT
|
0.020x |
|
ECSTELECOM Co. Ltd
KQ:067010
|
0.056x |
|
Teera-Mongkol Industry Public Company Limited
BK:TMI
|
0.096x |
|
Inotiv Inc
NASDAQ:NOTV
|
-0.050x |
|
Pertama Digital Berhad
KLSE:8532
|
0.104x |
Annual Cash Flow Conversion Efficiency for AEON Biopharma, Inc. (2019–2024)
The table below shows the annual cash flow conversion efficiency of AEON Biopharma, Inc. from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see market value of AEON Biopharma, Inc..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-28.57 Million | $-20.29 Million | 0.710x | +127.30% |
| 2023-12-31 | $-153.04 Million | $-47.83 Million | 0.312x | +137.47% |
| 2022-12-31 | $-270.41 Million | $-35.58 Million | 0.132x | +3.59% |
| 2021-12-31 | $-223.82 Million | $-28.43 Million | 0.127x | +172.88% |
| 2020-12-31 | $-203.23 Million | $-9.46 Million | 0.047x | -93.14% |
| 2019-12-31 | $-65.87 Million | $-44.73 Million | 0.679x | -- |
About AEON Biopharma, Inc.
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of ga… Read more